- Home
- HCWB vs GLMD Comparison
HCWB vs GLMD Comparison
Compare HCWB & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- GLMD
- Stock Information
- Founded
- HCWB 2018
- GLMD 2000
- Country
- HCWB United States
- GLMD Israel
- Employees
- HCWB N/A
- GLMD N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- HCWB Health Care
- GLMD Health Care
- Exchange
- HCWB Nasdaq
- GLMD Nasdaq
- Market Cap
- HCWB 8.7M
- GLMD 8.0M
- IPO Year
- HCWB 2021
- GLMD 2014
- Fundamental
- Price
- HCWB $4.00
- GLMD $1.59
- Analyst Decision
- HCWB Strong Buy
- GLMD Hold
- Analyst Count
- HCWB 1
- GLMD 1
- Target Price
- HCWB $35.00
- GLMD N/A
- AVG Volume (30 Days)
- HCWB 1.3M
- GLMD 81.5K
- Earning Date
- HCWB 11-13-2025
- GLMD 11-13-2025
- Dividend Yield
- HCWB N/A
- GLMD N/A
- EPS Growth
- HCWB N/A
- GLMD N/A
- EPS
- HCWB N/A
- GLMD N/A
- Revenue
- HCWB $832,841.00
- GLMD N/A
- Revenue This Year
- HCWB $178.64
- GLMD N/A
- Revenue Next Year
- HCWB N/A
- GLMD N/A
- P/E Ratio
- HCWB N/A
- GLMD N/A
- Revenue Growth
- HCWB N/A
- GLMD N/A
- 52 Week Low
- HCWB $2.77
- GLMD $1.15
- 52 Week High
- HCWB $100.80
- GLMD $4.81
- Technical
- Relative Strength Index (RSI)
- HCWB 47.15
- GLMD 58.87
- Support Level
- HCWB $3.66
- GLMD $1.35
- Resistance Level
- HCWB $4.13
- GLMD $1.63
- Average True Range (ATR)
- HCWB 0.21
- GLMD 0.09
- MACD
- HCWB 0.00
- GLMD 0.02
- Stochastic Oscillator
- HCWB 34.60
- GLMD 76.67
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.